

# On-X<sup>®</sup>

CE  
0459

## Prosthetic Heart Valve

### Instructions for Use English

On-X<sup>®</sup> Aortic Heart Valve with Standard Sewing Ring - REF ONXA

On-X<sup>®</sup> Mitral Heart Valve with Standard Sewing Ring - REF ONXM

On-X<sup>®</sup> Aortic Heart Valve with Conform-X<sup>®</sup> Sewing Ring - REF ONXAC

On-X<sup>®</sup> Mitral Heart Valve with Conform-X<sup>®</sup> Sewing Ring - REF ONXMC

On-X<sup>®</sup> Aortic Heart Valve with Anatomic Sewing Ring - REF ONXAN

On-X<sup>®</sup> Aortic Heart Valve and Extended Holder - REF ONXAE

On-X<sup>®</sup> Aortic Heart Valve with Conform-X<sup>®</sup> Sewing Ring and Extended Holder - REF ONXACE

On-X<sup>®</sup> Aortic Heart Valve with Anatomic Sewing Ring and Extended Holder - REF ONXANE

# ON-X® PROSTHETIC HEART VALVE

## INSTRUCTIONS FOR USE

On-X® Aortic Heart Valve with  
Standard Sewing Ring

On-X® Mitral Heart Valve with  
Standard Sewing Ring

On-X® Aortic Heart Valve with  
Conform-X® Sewing Ring

On-X® Mitral Heart Valve with  
Conform-X® Sewing Ring

On-X® Aortic Heart Valve with  
Anatomic Sewing Ring

On-X® Aortic Heart Valve and  
Extended Holder

On-X® Aortic Heart Valve with  
Conform-X® Sewing Ring and  
Extended Holder

On-X® Aortic Heart Valve with  
Anatomic Sewing Ring and  
Extended Holder

For more information visit  
[www.onxlti.com/ifu](http://www.onxlti.com/ifu)

## TABLE OF CONTENTS

|   |           |
|---|-----------|
| <b>ON-X® PROSTHETIC HEART VALVE</b> .....                 | <b>2</b>  |
| <b>INSTRUCTION FOR USE</b> .....                          | <b>4</b>  |
| <b>1. DEVICE DESCRIPTION</b> .....                        | <b>4</b>  |
| <b>2. INDICATIONS FOR USE</b> .....                       | <b>4</b>  |
| <b>3. CONTRAINDICATIONS</b> .....                         | <b>4</b>  |
| <b>4. WARNINGS AND PRECAUTIONS</b> .....                  | <b>5</b>  |
| 4.1 WARNINGS .....  | 5         |
| 4.2 PRECAUTIONS .....                                     | 5         |
| <b>5. POTENTIAL ADVERSE EVENTS</b> .....                  | <b>5</b>  |
| <b>6. INDIVIDUALIZATION OF TREATMENT</b> .....            | <b>5</b>  |
| 6.1 SPECIFIC PATIENT POPULATION .....                     | 5         |
| <b>7. PATIENT COUNSELING</b> .....                        | <b>5</b>  |
| <b>8. HOW SUPPLIED</b> .....                              | <b>6</b>  |
| 8.1 AVAILABLE MODELS AND SIZES .....                      | 6         |
| 8.2 PACKAGING .....                                       | 6         |
| 8.3 STORAGE .....   | 6         |
| 8.4 ACCESSORIES .....                                     | 7         |
| 8.5 ACCESSORY CLEANING AND STERILIZATION.....             | 8         |
| <b>9. DIRECTIONS FOR USE</b> .....                        | <b>8</b>  |
| 9.1 PHYSICIAN TRAINING .....                              | 8         |
| 9.2 STERILIZATION AND RESTERILIZATION .....               | 8         |
| 9.3 HANDLING AND PREPARATION INSTRUCTIONS .....           | 8         |
| 9.4 DEVICE IMPLANTATION .....                             | 10        |
| 9.5 SUTURING TECHNIQUES.....                              | 10        |
| 9.6 LEAFLET MOTION ASSESSMENT AND VALVE ROTATION.....     | 11        |
| 9.7 VALVE ORIENTATION .....                               | 12        |
| <b>10. POSTOPERATIVE INFORMATION</b> .....                | <b>12</b> |
| 10.1 MAGNETIC RESONANCE IMAGING (MRI) COMPATIBILITY ..... | 12        |
| 10.2 RETURNED GOODS .....                                 | 12        |
| <b>11. PATIENT INFORMATION</b> .....                      | <b>12</b> |
| 11.1 PATIENT REGISTRATION .....                           | 12        |
| 11.2 PATIENT RECORD CARD.....                             | 13        |
| 11.3 PATIENT INFORMATION BOOKLET.....                     | 13        |
| <b>12. DISCLAIMER OF WARRANTIES</b> .....                 | <b>13</b> |
| <b>APPENDIX A</b> .....                                   | <b>13</b> |
| <b>1. ADVERSE EVENTS</b> .....                            | <b>13</b> |
| 1.1 OBSERVED ADVERSE EVENTS .....                         | 13        |
| <b>2. CLINICAL STUDIES</b> .....                          | <b>13</b> |

## LIST OF FIGURES

|   |    |
|---|----|
| Figure 1: Aortic and Mitral Profiles .....                                  | 4  |
| Figure 2: Standard or Extended Aortic Valve Holders .....                   | 6  |
| Figure 3a: Sizer and Replica Sizer .....                                    | 7  |
| Figure 3b: Sizer .....  | 7  |
| Figure 4: Instrument Handle .....   | 8  |
| Figure 5: Rotator .....   | 8  |
| Figure 6: Leaflet Probe .....   | 8  |
| Figure 7a. Twist-off outer lid .....  | 9  |
| Figure 7b. Remove by pull tab... ..   | 9  |
| Figure 7c. ...or invert on sterile field.....                               | 9  |
| Figure 8a. Peel-off outer lid .....   | 9  |
| Figure 8b. Remove by pull tab... ..   | 9  |
| Figure 8c. ...or invert on sterile field .....                              | 9  |
| Figure 9. Opening the inner container.....                                  | 10 |
| Figure 10. Inserting the instrument handle.....                             | 10 |
| Figure 11. Aortic replica sizers verify the aortic valve.....               | 10 |
| Figure 12. Supra-annular valve positioning .....                            | 11 |
| Figure 13. Sewing ring cross-sections.....                                  | 11 |
| Figure 14. Removing the valve holder .....                                  | 11 |
| Figure 15. Insert valve rotator .....                                       | 12 |
| Figure 16. Pivot axis of the mitral valve positioned anti-anatomically..... | 12 |

## LIST OF CHARTS

|  |    |
|--|----|
| Chart 1: Patient Follow-up Over Time ..... | 15 |
|--|----|

## LIST OF TABLES

|   |    |
|---|----|
| Table 1: On-X Valve Specifications (millimeters).....             | 6  |
| Table 2: Sizer Selections - Regardless of Aortic Holder Type..... | 7  |
| Table 3: Aortic Replacement Observed Adverse Event Rates .....    | 15 |
| Table 4: Mitral Replacement Observed Adverse Event Rates.....     | 16 |
| Table 5: Preoperative Patient Demographics .....                  | 16 |
| Table 6: Operative Patient Demographics .....                     | 17 |
| Table 7: Number Implanted and Years by Valve Size.....            | 18 |
| Table 8: Valve Effectiveness Outcomes .....                       | 18 |
| Table 9: Effectiveness Outcomes, Hemodynamic Results.....         | 19 |

# INSTRUCTION FOR USE

**CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.**

## 1. DEVICE DESCRIPTION

The On-X<sup>®</sup> Prosthetic Heart Valve (Figure 1) is a bileaflet mechanical heart valve, which consists of an orifice housing and two leaflets. The orifice inflow area has a flared inlet designed to reduce flow turbulence, and the outflow rim consists of leaflet guards designed to protect the leaflets while in the closed position. The leaflets rotate around tabs located within the inner circumference of the orifice ring. In the closed position, each leaflet forms a nominal angle of 40° relative to the plane of the orifice. In the open position, the plane of each leaflet forms a nominal angle of 90° relative to the plane of the orifice. The leaflets have a travel arc of 50° to the closed position.

The orifice is composed of graphite substrate coated with On-X<sup>®</sup> Carbon, a pure unalloyed form of pyrolytic carbon. The leaflets consist of On-X<sup>®</sup> Carbon deposited on a graphite substrate, which is impregnated with 10 weight% tungsten to provide radiopacity.

The sewing ring is constructed of polytetrafluoroethylene (PTFE) fabric mounted on the orifice using titanium retaining rings and 5-0 suture material. This form of sewing ring attachment to the orifice allows for rotation of the sewing ring in situ during implantation. Orientation reference marks are provided on the sewing ring for valve orientation.

The On-X<sup>®</sup> Prosthetic Heart Valve is available in 3 aortic and 2 mitral sewing ring configurations. All aortic configurations are available in sizes 19, 21, 23, 25, and 27/29 mm. The standard mitral sewing ring is available in sizes 23, 25, 27/29 and 31/33, while the mitral Conform-X<sup>®</sup> sewing ring is available in size 25/33 only.

Aortic valves, size 19 mm through 25 mm, are designed for intrasupra-annular sewing ring position, while the valve size 27/29 mm is designed for intra-annular sewing ring position. All mitral valve sizes are designed for the supra-annular sewing ring position.


## 2. INDICATIONS FOR USE

The On-X Prosthetic Heart Valve is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic heart valves in the aortic and mitral positions.

## 3. CONTRAINDICATIONS

The On-X Prosthetic Heart Valve is contraindicated for patients unable to tolerate anticoagulation therapy.

**Figure 1: Aortic and Mitral Profiles**  
(See Table 1 for corresponding dimensions)



## 4. WARNINGS AND PRECAUTIONS

### 4.1 Warnings

#### FOR SINGLE USE ONLY.

**DO NOT use the On-X Prosthetic Heart Valve if:**

- the prosthesis has been dropped, damaged, or mishandled in any way;
- the expiration date has elapsed;
- the tamper evident seal is broken;
- the serial number tag does not match the serial number on the container label.

**DO NOT pass a catheter, surgical instrument, or transvenous pacing lead through the prosthesis as this may cause valvular insufficiency, leaflet damage, leaflet dislodgment, and/or catheter/instrument/lead entrapment.**

**DO NOT resterilize the On-X Prosthetic Heart Valve.**

### 4.2 Precautions

**Handle the prosthesis with only On-X Life Technologies, Inc. (On-XLTI) On-X Prosthetic Heart Valve Instruments. Only On-XLTI On-X Prosthetic Heart Valve sizers should be used during the selection of the valve size; other sizers may result in improper valve selection.**

**Avoid contacting the carbon surfaces of the valve with gloved fingers or any metallic or abrasive instruments as they may cause damage to the valve surface not seen with the unaided eye that may lead to accelerated valve structural dysfunction, leaflet escape, or serve as a nidus for thrombus formation.**

**Avoid damaging the prosthesis through the application of excessive force to the valve orifice or leaflets.**

## 5. POTENTIAL ADVERSE EVENTS

Adverse events potentially associated with the use of prosthetic heart valves (in alphabetical order) include, but are not limited to:

- angina
- cardiac arrhythmia
- endocarditis
- heart failure
- hemolysis
- hemolytic anemia
- hemorrhage
- myocardial infarction
- prosthesis leaflet entrapment (impingement)
- prosthesis nonstructural dysfunction
- prosthesis pannus
- prosthesis perivalvular leak
- prosthesis regurgitation
- prosthesis structural dysfunction

- prosthesis thrombosis
- stroke
- thromboembolism

It is possible that these complications could lead to:

- reoperation
- explantation
- permanent disability
- death

Mechanical prosthetic heart valves produce audible sounds as a normal function of their operation. In some patients, these sounds may be objectionable.

### **Risk of Re-Use Statement**

In accordance with the EU Medical Device Directive, 93/42/EEC, Annex I, Section 13.6h, the device manufacturer must provide information on risks associated with re-use of a single use device. Therefore, the following statement is provided:

The implanted On-X prosthetic heart valve is designed for single use only. Do not re-use the device. In addition to the risks listed in Section 5, re-use may cause procedural complications including device damage, compromised device biocompatibility, and device contamination. Re-use may result in infection, serious injury, or patient death.

## 6. INDIVIDUALIZATION OF TREATMENT

Adequate anticoagulant or anticoagulant/antiplatelet therapy should be administered. Selection of an anticoagulant or anticoagulant/antiplatelet regimen is based on the particular needs of the patient and the clinical situation.

### 6.1 Specific Patient Population

The safety and effectiveness of the On-X Prosthetic Heart Valve has not been established for the following specific populations because it has not been studied in these populations:

- patients who are pregnant;
- nursing mothers;
- patients with chronic endocarditis;
- patients requiring pulmonary or tricuspid replacement.

## 7. PATIENT COUNSELING

- Prophylactic antibiotic treatment must be provided to all patients with prosthetic valves undergoing dental procedures or other potentially bacteremic procedures.
- Patients require anticoagulation or anticoagulant/antiplatelet therapy.
- Patients should be encouraged to complete the Patient ID card provided with the valve and carry it with them at all times.

## 8. HOW SUPPLIED


### 8.1 Available Models and Sizes

The On-X Prosthetic Heart Valve is available in 3 aortic and 2 mitral sewing ring configurations. All aortic configurations are available in sizes 19, 21, 23, 25, and 27/29 mm. The standard mitral sewing ring is available in sizes 23, 25, 27/29 and 31/33 mm, while the Mitral Conform-X sewing ring is available in size 25/33 only.

Aortic valves, size 19 mm through 25 mm, are designed for intrasupra-annular sewing ring position, while the valve size 27/29 mm is designed for intra-annular sewing ring position. All mitral valve sizes are designed for the supra-annular sewing ring position.

Aortic valves are available with either standard or extended valve holders (Figure 2).

**Figure 2: Standard or Extended Aortic Valve Holders**



The dimensional and model specifications for all available sizes of the On-X Prosthetic Heart Valve are shown in Table 1 and Figure 1. The symbol SZ mm on the box, container labels, and implant registration card refers to the tissue annulus diameter of the valve in millimeters.

### 8.2 Packaging

The On-X Prosthetic Heart Valve is provided sterile, mounted on a holder, in a double-sealed plastic container. The package consists of the following items:

- Outer box
- Patient record card
- Plastic valve container
- Implant registration card
- Plastic valve holder
- Valve serial number tag
- Instructions for use

Instruments for implantation of the On-X Prosthetic Heart Valve are supplied separately, **NON-STERILE**, and must be cleaned and sterilized prior to use as outlined in section 8.5.

### 8.3 Storage

The On-X Prosthetic Heart Valve has been qualified for a maximum storage life of 5 years from the date of manufacture for the twist-off lid design, or 6 years for the peel-off lid design. The sterility expiration date of the On-X Prosthetic Heart Valve is recorded on the outer package label. Appropriate inventory control should be maintained so that prostheses with earlier expiration dates are preferentially implanted and expiration is avoided. To protect the valve, it should be stored in its outer box until used. The storage environment should be clean, cool, and dry.

**Table 1: On-X Valve Specifications (millimeters)**

| Model Designator |                 |                        | Tissue Annulus (mounting) Diameter (A) | Orifice Internal Diameter (D) | External Sewing Ring Diameter (S) | Profile Height (closed) (h) | Profile Height (open) (H) | Internal Orifice Area (mm <sup>2</sup> ) |
|------------------|-----------------|------------------------|--|-------------------------------|-----------------------------------|-----------------------------|---------------------------|--|
| Extended Holder  | Standard Holder | Size/Type              |  |                               |                                   |                             |                           |  |
| ONXAE-19*        | ONXA-19         | 19 Aortic              | 19                                     | 17.4                          | 23                                | 10.8                        | 13.3                      | 228                                      |
| ONXAE-21*        | ONXA-21         | 21 Aortic              | 21                                     | 19.4                          | 26                                | 11.9                        | 14.7                      | 284                                      |
| ONXAE-23*        | ONXA-23         | 23 Aortic              | 23                                     | 21.4                          | 29                                | 13.1                        | 16.1                      | 344                                      |
| ONXAE-25*        | ONXA-25         | 25 Aortic              | 25                                     | 23.4                          | 32                                | 14.2                        | 17.8                      | 411                                      |
| ONXAE-27/29*     | ONXA-27/29      | 27/29 Aortic           | 27-29                                  | 23.4                          | 34                                | 14.2                        | 17.8                      | 411                                      |
| ONXACE-19*       | ONXAC-19*       | 19 Aortic Conform-X    | 19                                     | 17.4                          | 27                                | 10.8                        | 13.3                      | 228                                      |
| ONXACE-21*       | ONXAC-21*       | 21 Aortic Conform-X    | 21                                     | 19.4                          | 30                                | 11.9                        | 14.7                      | 284                                      |
| ONXACE-23*       | ONXAC-23*       | 23 Aortic Conform-X    | 23                                     | 21.4                          | 33                                | 13.1                        | 16.1                      | 344                                      |
| ONXACE-25*       | ONXAC-25*       | 25 Aortic Conform-X    | 25                                     | 23.4                          | 34                                | 14.2                        | 17.8                      | 411                                      |
| ONXACE-27/29*    | ONXAC-27/29*    | 27/29 Aortic Conform-X | 27-29                                  | 23.4                          | 36                                | 14.2                        | 17.8                      | 411                                      |
| ONXANE-19*       | ONXAN-19*       | 19 Aortic Anatomic     | 19                                     | 17.4                          | 27                                | 10.8                        | 13.3                      | 228                                      |
| ONXANE-21*       | ONXAN-21*       | 21 Aortic Anatomic     | 21                                     | 19.4                          | 30                                | 11.9                        | 14.7                      | 284                                      |
| ONXANE-23*       | ONXAN-23*       | 23 Aortic Anatomic     | 23                                     | 21.4                          | 33                                | 13.1                        | 16.1                      | 344                                      |
| ONXANE-25*       | ONXAN-25*       | 25 Aortic Anatomic     | 25                                     | 23.4                          | 34                                | 14.2                        | 17.8                      | 411                                      |
| ONXANE-27/29*    | ONXAN-27/29*    | 27/29 Aortic Anatomic  | 27-29                                  | 23.4                          | 36                                | 14.2                        | 17.8                      | 411                                      |
|                  | ONXM-23**       | 23 Mitral              | 23                                     | 21.4                          | 31                                | 13.1                        | 16.1                      | 344                                      |
|                  | ONXM-25         | 25 Mitral              | 25                                     | 23.4                          | 33                                | 14.2                        | 17.8                      | 411                                      |
|                  | ONXM-27/29      | 27/29 Mitral           | 27-29                                  | 23.4                          | 34                                | 14.2                        | 17.8                      | 411                                      |
|                  | ONXM-31/33      | 31/33 Mitral           | 31-33                                  | 23.4                          | 36                                | 14.2                        | 17.8                      | 411                                      |
|                  | ONXMC-25/33     | Mitral Conform-X       | 25-33                                  | 23.4                          | 39                                | 14.2                        | 17.8                      | 411                                      |

\* Not available in all markets

\*\* Not available in the USA

Refer to Figure 1 for location of measured dimensions. Values given are nominal within the tolerance band.

## 8.4 Accessories

The On-X Prosthetic Heart Valve is designed to be used only with On-XLTI On-X instruments. The instruments, supplied separately, are provided as a set, which includes sizers, rotators, an instrument handle, and a leaflet probe. The instruments are reusable.

**CAUTION: Sizers and instrument handles have metallic regions that are bendable. Repeated bending of these metallic regions can lead to fatigue and fracture. To avoid instrument fracture during use, the stem should be inspected for surface cracks before and after each time it is bent. If metal fatigue surface cracks are present, the sizer and/or instrument handle should be discarded and replaced. Contact On-XLTI Customer Service to order replacements.**

**CAUTION: Leaflet probes and rotators are flexible, but are not intended to be bent to a permanently deformed state.**

### Sizer

The sizer is used to gauge the resulting tissue annulus diameter after the annulus is prepared for implant. The sizer has a bendable stem on each end. The sizers are cylindrical for size 19 mm through 25 mm valves and conical for size 27/29 mm and 31/33 mm valves (Figure 3a and 3b). To facilitate sizer selection, refer to Table 2.

### Replica Sizers

Aortic replica sizers are provided for all aortic valve sizes (Figure 3a). They model the On-X standard aortic valve profile. They are used after sizing for standard, Conform-X, and Anatomic sewing ring configurations to assure fit of the aortic valve without obstruction of the coronary arteries. The size 19 through 25 aortic replica sizers shape is intended to model intrasupra-annular positioning. The size 27/29 aortic replica sizer is intended to model intra-annular positioning.

Figure 3a: Sizer and Replica Sizer




Figure 3b: Sizer




Table 2: Sizer Selections - Regardless of Aortic Holder Type

| Size   | Valve Type       | Sizer Choice           |                     | Position of sewing ring |
|--------|------------------|------------------------|---------------------|-------------------------|
|        |                  | Sizer Type             | Use Replicate Sizer |                         |
| 19     | Aortic           | Cylindrical            | YES                 | Intrasupra-annular      |
| 21     | Aortic           | Cylindrical            | YES                 | Intrasupra-annular      |
| 23     | Aortic           | Cylindrical            | YES                 | Intrasupra-annular      |
| 25     | Aortic           | Cylindrical            | YES                 | Intrasupra-annular      |
| 27/29  | Aortic           | Conical                | YES                 | Intra-annular           |
| 19*    | Aortic Conform-X | Cylindrical            | YES                 | Intrasupra-annular      |
| 21*    | Aortic Conform-X | Cylindrical            | YES                 | Intrasupra-annular      |
| 23*    | Aortic Conform-X | Cylindrical            | YES                 | Intrasupra-annular      |
| 25*    | Aortic Conform-X | Cylindrical            | YES                 | Intrasupra-annular      |
| 27/29* | Aortic Conform-X | Conical                | YES                 | Intra-annular           |
| 19*    | Aortic Anatomic  | Cylindrical            | YES                 | Intrasupra-annular      |
| 21*    | Aortic Anatomic  | Cylindrical            | YES                 | Intrasupra-annular      |
| 23*    | Aortic Anatomic  | Cylindrical            | YES                 | Intrasupra-annular      |
| 25*    | Aortic Anatomic  | Cylindrical            | YES                 | Intrasupra-annular      |
| 27/29* | Aortic Anatomic  | Conical                | YES                 | Intra-annular           |
| 23*    | Mitral           | Cylindrical            | NO                  | Supra-annular           |
| 25     | Mitral           | Cylindrical            | NO                  | Supra-annular           |
| 27/29  | Mitral           | Conical                | NO                  | Supra-annular           |
| 31/33  | Mitral           | Conical                | NO                  | Supra-annular           |
| 25/33  | Mitral Conform-X | Cylindrical or Conical | NO                  | Supra-annular           |

\* Not available in all markets

### Instrument Handle

The instrument handle (Figure 4) facilitates holding the valve or the rotator during surgery. The instrument handle is comprised of a grip, a bendable stem, and a tip.

### Rotator

The valve rotator (Figure 5) is used for reorienting an in situ valve and may be used to verify leaflet mobility. The rotator consists of a plastic head with a centrally located leaflet probe and an attached handle.

The rotator may be used with or without the instrument handle attached. To attach the rotator to the instrument handle, insert the instrument handle tip directly into the slot on the end of the rotator handle. The rotator snaps into place after the application of a light insertion force.

### Leaflet Probe

The leaflet probe (Figure 6) is a flexible rod with tapered ends. The leaflet probe may be used to gently move the leaflets to verify that they open and close freely.




Figure 4: Instrument Handle

Figure 5: Rotator




Figure 6: Leaflet Probe

### 8.5 Accessory Cleaning and Sterilization

Instruments for implantation of the On-X Prosthetic Heart Valve are supplied separately, NON-STERILE, and must be cleaned and sterilized prior to use. Standard hospital surgical instrument cleaning procedures must be used. Note: the metallic instruments are made of titanium. The plastic instruments are made of polyphenylsulfone. Materials used in these instruments can withstand standard steam and flash steam sterilization.

**WARNING:** These instruments are NOT provided sterile. They must be properly cleaned and sterilized prior to each use.

**WARNING:** DO NOT sterilize instruments with any method of sterilization other than steam. Damage to some items could result from use of other sterilization methods.

**WARNING:** The rotator must be removed from the handle after use and prior to cleaning. A force greater than the insertion force is required to remove the rotator from the instrument handle.

### 9. DIRECTIONS FOR USE

**WARNING:** DO NOT use the On-X Prosthetic Heart Valve if:

- the prosthesis has been dropped, damaged, or mishandled in any way;
- the expiration date has elapsed;
- the tamper evident seal is broken;
- the serial number tag does not match the serial number on the container label.

#### 9.1 Physician Training

No special training is required to implant the On-X Prosthetic Heart Valve. The techniques for implanting this prosthesis are similar to those used for any mechanical heart valve prosthesis.

#### 9.2 Sterilization and Resterilization

The On-X Prosthetic Heart Valve is provided sterile. If the sterility expiration date has passed or if upon removal from the outer box, the valve container is damaged or the sterility barrier is broken, do not use the valve. Call On-XLTI Customer Service and arrange to return the valve and receive a replacement.

**WARNING:** If during surgery the valve is removed from its container but not used, it must not be repackaged or resterilized. In this situation, the valve must be returned to On-XLTI. Call Customer Service for information before any return is made.

**WARNING:** Do not resterilize the On-X Prosthetic Heart Valve.

#### 9.3 Handling and Preparation Instructions

**CAUTION:** Handle the prosthesis with only On-XLTI On-X Prosthetic Heart Valve Instruments. Only On-XLTI On-X Prosthetic Heart Valve sizes should be used during the selection of the valve size; other sizes may result in improper valve selection.

**CAUTION:** Avoid contacting the carbon surfaces of the valve with gloved fingers or any metallic or abrasive instruments as they may cause damage to the valve surface not seen with the unaided eye that may lead to accelerated valve structural dysfunction, leaflet escape, or serve as a nidus for thrombus formation.

**CAUTION:** Avoid damaging the prosthesis through the application of excessive force to the valve orifice or leaflets.



### Circulating Nurse

1. Check the expiration date on the outer box.

**WARNING: DO NOT use the On-X Prosthetic Heart Valve if the expiration date has elapsed. If a valve is unused, its plastic container is undamaged, and the sterility expiration date has passed, the valve should be returned to On-XLTI.**

2. Remove the valve container and package inserts from the outer box. Inspect the container for damage.

**WARNING: DO NOT use the On-X Prosthetic Heart Valve if the prosthesis has been dropped, damaged, or mishandled in any way. If any damage is found, use another valve and arrange for a return through On-XLTI Customer Service.**

3. Fill out the implant registration card as completely as local law allows and return to On-XLTI as soon as possible. This allows the patient to be entered into the tracking database, which could be important for future notices regarding the valve. Give the patient record card to the patient or place it in the patient's records.

4. Open the outer container

**Twist-off outer lid package design:** Rotate the lid counter-clockwise until it stops, then lift the lid off of the container (Figure 7a).

**Peel-off Tyvek® lid package design:** Grasp the peel tab corner of the lid and pull back towards the center of the container (Figure 8a). Continue peeling until the lid is completely removed.

5. The scrub nurse may remove the sterile inner container from the outer container by gently lifting the pull tab attached to the top of the inner container (Figure 7b or Figure 8b). The inner container is then placed onto the instrument tray. Alternately, the inner container can be placed on the sterile field by gently inverting the outer container slightly above the sterile field (Figure 7c or Figure 8c) and allowing the inner container to slip out onto the sterile field.

### Twist-off Lid Design

Figure 7a. Twist-off outer lid



Figure 7b. Remove by pull tab...





Figure 7c. ...or invert on sterile field



### Peel-off Lid Design

Figure 8a. Peel-off outer lid



Figure 8b. Remove by pull tab...




Figure 8c. ...or invert on sterile field



**Scrub Nurse/Surgeon:**

1. Check the tamper evident seal of the inner container.

**WARNING: DO NOT use the On-X Prosthetic Heart Valve if the tamper evident seal has been broken. If the tamper evident seal has been broken, use another valve and arrange for return through On-XLTI Customer Service.**

2. Open the inner container by gently twisting the lid to break the tamper-proof seals (Figure 9) and then lifting the lid off the base.
3. Press the instrument handle tip into the slot on the valve holder until it snaps firmly into position (Figure 10). Gently lift the valve out of the container and slide the holder plate off the holder.

Carefully grasp the sewing ring with a gloved hand using a light grip and gently turn the instrument handle in either direction. The valve should easily rotate within the sewing ring. Stop rotation testing with an orientation mark aligned with the pivot axis.

**WARNING: DO NOT use the On-X Prosthetic Heart Valve if the valve does not rotate easily. Use another valve and arrange for return through On-XLTI Customer Service.**

Figure 9. Opening the inner container




Figure 10. Inserting the instrument handle

4. Check the serial number tag against the label on the outer container.

**WARNING: DO NOT use the On-X Prosthetic Heart Valve if the serial number tag does not match the container label. Use another valve and arrange for a return through On-XLTI Customer Service.**

5. Remove the serial number tag by cutting the suture that holds it on the valve. If desired, the tag can be used to check for sterility by standard culture techniques immediately after it is removed.

6. The valve is now ready for implantation. To ease positioning during implantation, the instrument handle stem can be bent by grasping the ends of the handle and the stem, then bending. Avoid grasping the valve.

**WARNING: DO NOT use the valve for leverage in bending the instrument handle. This could damage the valve and lead to mechanical failure.**

**9.4 Device Implantation**

**WARNING: All accessory instruments must be cleaned and sterilized prior to use according to the instrument instructions.**

**Sizing**


Use only On-X Prosthetic Heart Valve sizers when sizing the annulus. Sizers contain cylindrical, conical, and aortic replica ends. Refer to Table 2 to facilitate sizer selection.

Cylindrical sizers correspond to the valve sizes 19 mm through 25 mm. Conical sizers correspond to the valve size 27/29 mm and 31/33 mm. These types of sizers may be used for both aortic and mitral valves.

The correct valve size is determined by obtaining a comfortable, not tight, fit of the sizer within the annulus. When a comfortable fit is found, the corresponding valve size is signified by the identification on the sizer. On-X Mitral Conform-X Prosthetic Heart Valves may be used when a comfortable fit is at or between size 25 and size 33.

Aortic replica sizers are provided for all aortic valve sizes. For size 19 mm through 25 mm aortic valves, the aortic replica sizers are used to verify that the aortic valve can be properly seated in the annulus and that the coronary arteries remain unobstructed. Size 19 mm through 25 mm aortic valves of standard, Conform-X, and Anatomic sewing ring configurations are designed to fit within the annulus at implant such that the exposed carbon flare rests in the annulus and the sewing ring is intrasupracoronary (Figure 11).

Figure 11. Aortic replica sizers verify the aortic valve




**WARNING: DO NOT size the sewing ring of the size 19 mm through 25 mm aortic valve to fit within the annulus.**

Size 27/29 mm aortic valves of standard, Conform-X, and Anatomic sewing ring configurations are designed to be placed in an intra-annular position and have a replica sizer to mimic this placement.

All mitral valves, including the On-X Mitral Conform-X Prosthetic Heart Valve, are designed to be placed in a supra-annular position (Figure 12).

**CAUTION: Avoid oversizing the valve, as this could lead to interference with valve function.**

**Figure 12. Supra-annular valve positioning**



### 9.5 Suturing Techniques

The suturing techniques vary according to the preferences of the implanting surgeon and patient condition. The aortic valve is designed to have the tissue annulus about the orifice flare. The general consensus among surgeons is that the non-everting interrupted mattress suture technique, with or without pledgets, provides the best conformation of the valve annulus to the outer surface of the flare.


The mitral valves have generally been implanted using a pledgetted or non-pledgetted everting mattress suture technique, although non-everting and continuous suture techniques have also been used with success.

**CAUTION: When seating the valve, ensure that no suture material or anatomic structures interfere with leaflet motion. The valve's rotation capability may be helpful in avoiding abnormal residual pathology that could interfere with leaflet motion.**

The sutures should be passed through the mid-point of the sewing ring. This allows the sewing ring to remain flexible and conform to the annulus. It also prevents the suture needle from contacting the titanium rings that lie within the sewing ring (Figure 13). The orientation marks on the sewing ring may be used to aid in suture placement.

**CAUTION: For the Anatomic sewing ring, the sutures at the three valve commissures must correspond to the three orientation marks on the sewing ring.**

**Figure 13. Sewing ring cross-sections**




When all the sutures are in place, the valve is advanced into the annulus and the sutures are tied down. For aortic valves, it is suggested that the first 3 knots be tied equidistant to one another and midway between the commissures to stabilize the valve in the annulus. The holder is removed from the valve by carefully cutting the retaining suture as shown in Figure 14, then gently lifting the valve holder with handle out of the valve.

**WARNING: Do NOT attempt to reinsert the valve holder into the valve once it has been removed.**

**CAUTION: Suture ties should be cut short to avoid any potential interference with leaflet motion.**

**Figure 14. Removing the valve holder**



## 9.6 Leaflet Motion Assessment and Valve Rotation

### Leaflet Motion Testing

Once the valve is in place, free motion of the leaflets must be tested. To test leaflet mobility, use the rotator probe or the leaflet probe to gently move the leaflets to verify that they open and close freely.

**WARNING: Test the leaflet mobility only with the On-XLTI On-X leaflet probe or the leaflet probe on the end of the rotator.**

### Rotation

If the leaflets do not move freely, gently rotate the valve in either direction until it reaches a position where leaflet interference is not encountered.

**CAUTION: Do not attempt to rotate the valve if any significant resistance to rotation is encountered. The torque required to rotate the valve in situ should be about the same as that required when testing rotation before implantation. If noticeably greater torque is required to rotate, stop attempting rotation. If rotation is necessary and cannot be performed, remove the valve.**

The rotator may be used with or without the instrument handle attached. As needed, attach the instrument handle to the rotator by inserting the instrument handle tip into the slot on the end of the rotator handle until it snaps firmly into position.


**WARNING: Use only the On-XLTI On-X rotator to rotate the valve in situ. Use only the correspondingly sized rotator. Use of the wrong size rotator could damage the valve.**

With the rotator leaflet probe between the leaflets and the cross-bar aligned with the leaflet pivot axis of the valve, carefully insert the valve rotator into the valve until it seats easily in place (Figure 15).

**CAUTION: No resistance should be experienced when inserting the rotator. If resistance is encountered, stop, remove, and realign the rotator before attempting to insert the rotator again.**

Retest leaflet motion after rotation. If free leaflet motion cannot be achieved, remove the valve.

Figure 15. Insert valve rotator



## 9.7 Valve Orientation

### Aortic:


Based on clinical studies, there is no preferred orientation for the Aortic On-X Prosthetic Heart Valves with the standard, Conform-X, or Anatomic sewing ring configurations.

**CAUTION: Once the valve is implanted, visually confirm that the coronary ostia are free from potential interference.**

### Mitral:

Literature suggests that the pivot axis of the mitral valve should be positioned anti-anatomically. Refer to Figure 16.

Figure 16. Pivot axis of the mitral valve positioned anti-anatomically



Mitral Standard and Conform-X

## 10. POSTOPERATIVE INFORMATION

### 10.1 Magnetic Resonance Imaging (MRI)

#### Compatibility

#### MR Conditional:



The On-X Prosthetic Heart Valve, Mitral Conform-X Heart Valve Prosthesis, Size 25-33\*, was determined to be MR-conditional according to the terminology specified in the American Society for Testing and Materials (ASTM) International, Designation: F2503-08. Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment. ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, Pennsylvania.

Non-clinical testing demonstrated that the On-X Mitral Conform-X Heart Valve Prosthesis, Size 25-33, is MR Conditional. A patient with this device can be scanned safely immediately after placement under the following conditions:

#### Static Magnetic Field:

- Static magnetic field of 3-Tesla or less
- Maximum spatial gradient magnetic field of 720-Gauss/cm or less

**MRI-Related Heating:**

In non-clinical testing, the On-X Prosthetic Heart Valve, Mitral Conform-X Heart Valve Prosthesis, Size 25-33, produced the following temperature rise during MRI performed for 15-min of scanning (i.e., per pulse sequence) in the 3-Tesla (3-Tesla/128-MHz, Excite, HDx, Software 14X.M5, General Electric Healthcare, Milwaukee, WI) MR system:

Highest temperature change +1.6°C

Therefore, the MRI-related heating experiments for the On-X Mitral Conform-X Heart Valve Prosthesis, Size 25-33, at 3-Tesla, using a transmit/receive RF body coil at an MR system reported whole body averaged SAR of 2.9-W/kg (i.e., associated with a calorimetry measured whole body averaged value of 2.7-W/kg), indicated that the greatest amount of heating that occurred in association with these specific conditions was equal to or less than +1.6°C.

**Artifact Information:**

MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the On-X Mitral Conform-X Heart Valve Prosthesis, Size 25-33. Therefore, optimization of MR imaging parameters to compensate for the presence of this device may be necessary.

| Pulse Sequence | Signal Void Size (mm <sup>2</sup> ) | Plane Orientation |
|----------------|-------------------------------------|-------------------|
| T1-SE          | 1,090                               | Parallel          |
| T1-SE          | 686                                 | Perpendicular     |
| GRE            | 1,478                               | Parallel          |
| GRE            | 1,014                               | Perpendicular     |

\*The MRI findings apply to this specific largest heart valve prosthesis and all other smaller sizes which are made from similar materials.

**10.2 Returned Goods**

Prior authorization from On-XLTI Customer Service is required for the return of any product. For any questions regarding the valve or for return authorization, please contact Customer Service.

Licensed under U.S. Patent Nos. 5,308,361; 5,137,532; 5,545,216; 5,772,694; 5,641,324; 5,908,452; 5,284,676; 5,305,554; 5,328,713, 5,332,337; 5,336,259; 5,514,410; 5,677,061; 6,096,075; Serial No. 09/010,449 allowed; Serial No. 09/224,816 allowed; and other permits and patents pending.

**11. PATIENT INFORMATION****11.1 Patient Registration**

In each valve package, there is a Patient Record Card and an Implant Registration Card. On-XLTI requests that the Implant Registration Card be filled out immediately and that the mailing copy be returned to On-XLTI Customer Service. For multiple valve implants, please fill out a card for each valve. On-XLTI will use these data for notification purposes and to help with inventory restocking in the hospital. All patient information remains strictly confidential, and the release of patient-identifying information can be refused if allowed by law.

**11.2 Patient Record Card**

A Patient Record Card is provided with the prosthesis. Patients should be encouraged to complete the card and carry it with them at all times.

**11.3 Patient Information Booklet**

On-XLTI has made available a patient information booklet that the physician may choose to provide to the patient prior to discharge. Copies of this booklet are available on request from your On-XLTI sales representative.

**12. DISCLAIMER OF WARRANTIES**

Because of the complications listed previously that may occur with the use of any heart valve prosthesis and the possibilities of damage, also noted previously, before, during or after implantation, On-XLTI warrants only that the product shall conform to On-XLTI's standard specifications. No other warranty is made by On-XLTI concerning the function of the product in use, and On-XLTI assumes no risk whatsoever as to the results of the use of this product. The entire risk with use of the product is that of the buyer. On-XLTI disclaims all other warranties, respecting the product, expressed or implied, including but not limited to those related to the product's merchantability or fitness for a particular purpose. On-XLTI shall not be liable for any direct, special, consequential or incidental loss, damage or expense related to the use of the product. No person has any authority to alter any of these conditions or to bind On-XLTI to any additional responsibility or warranty in connection with the use of the product.

## APPENDIX A

Clinical information as required by FDA (USA)

### 1. ADVERSE EVENTS

A total of 184 aortic On-X Prosthetic Heart Valves were implanted in 184 patients at 11 centers. The mean follow-up was 2.2 years (range of 0 to 4.0 years) with a total of 411.8 patient-years. In the mitral position 229 valves were implanted in 229 patients at 16 centers. Mean mitral follow-up was 1.8 years (range of 0 to 4.5 years) with a total of 417.9 patient-years.

In aortic patients, a total of 7 deaths occurred during the study and 2 of these were characterized as valve-related. The causes of the aortic valve-related deaths were early thromboembolism (1 patient) and sudden, unexplained death (1 patient). In mitral patients, a total of 18 deaths occurred during the study and 3 of these were characterized as valve-related. The causes of the mitral valve-related deaths were early, uncontrolled bleeding (1 patient) and sudden, unexplained death (2 patients).

#### 1.1 Observed Adverse Events

Adverse events were reported in the clinical study as shown in Tables 3 and 4

### 2. CLINICAL STUDIES


The On-X Prosthetic Heart Valve clinical trials were designed to study the safety and effectiveness of the valve in aortic and mitral valve replacement. Patients requiring isolated aortic heart valve replacement were enrolled from 1996 to 2000 at 11 centers in an international multicenter, prospective, non-randomized study with retrospective controls. Patients requiring isolated mitral heart valve replacement were enrolled from 1996 to 2001 at 16 centers in an international multicenter, prospective, non-randomized study with retrospective controls.

The aortic cohort included 184 patients (121 men, 63 women), aged from 20 to 80 years (mean of 60.2 years). The cumulative follow-up was 411.8 patient-years with a mean follow-up of 2.2 years (SD = 0.8 years, range = 0 to 4.0 years). The mitral cohort included 229 patients (86 men, 143 women), aged from 21 to 78 years (mean of 59.2 years). The cumulative follow-up was 417.9 patient-years with a mean follow-up of 1.8 years (SD = 1.3 years, range = 0 to 4.5 years). Tables 3 and 4 present preoperative and operative patient demographics. Figure 14 shows the number of patients implanted versus duration of follow-up. Tables 5 presents implant information by valve size, including the number of patients implanted and the number of patient-years.

Safety endpoints captured in the studies were complications; blood analyses were used to confirm the absence or presence of certain complications. Safety results are provided in Tables 1 and 2. Effectiveness endpoints were New York Heart Association (NYHA) classification and echocardiographic assessments. NYHA and blood data were obtained pre-operatively, intra-operatively, and post-operatively at 3 to 6 months, at one year, and annually thereafter. Hemodynamic data were obtained at discharge and at one year. Tables 6 and 7 present these effectiveness results.

### Chart 1: Patient Follow-up Over Time

Aortic patients implanted N = 184,  
 Cumulative follow-up = 411.8 patient-years  
 Mitral patients implanted N = 229,  
 Cumulative follow-up = 417.9 patient-years



| Patients Followed, Nf | Discharge | 1 Year Postoperative | 2 Year Postoperative | 3 Year Postoperative |
|-----------------------|-----------|----------------------|----------------------|----------------------|
|                       | Aortic    | 184                  | 138                  | 66                   |
| Mitral                | 216       | 134                  | 74                   | 44                   |

**Table 3: Aortic Replacement Observed Adverse Event Rates<sup>1</sup>**

All patients implanted, N = 184, Cumulative follow-up = 411.8 patient-years

| Complication                    | Early Events |                      | Late Events <sup>2</sup> |             | Freedom from Event <sup>3</sup> , % [SE] |                             |
|---------------------------------|--------------|----------------------|--------------------------|-------------|--|-----------------------------|
|                                 | n            | % (n/N) <sup>4</sup> | n                        | %/pt-yr     | 1 Year Postoperative (n=138)             | 3 Year Postoperative (n=37) |
| Mortality (all)                 | 4            | 2.2%                 | 3                        | 0.7%        | 97.8% [1.1]                              | 96.0% [1.5]                 |
| Mortality (valve-related)       | 1            | 0.5%                 | 1                        | 0.2%        | 99.4% [0.5]                              | 98.8% [0.9]                 |
| Endocarditis                    | 0            | 0.0%                 | 2                        | 0.5%        | 99.4% [0.6]                              | 98.9% [0.8]                 |
| Explant                         | 1            | 0.5%                 | 2                        | 0.5%        | 98.4% [0.9]                              | 97.8% [1.1]                 |
| <b>Hemolysis<sup>5</sup></b>    | <b>0</b>     | <b>0.0%</b>          | <b>0</b>                 | <b>0.0%</b> | <b>100.0% [0]</b>                        | <b>100.0% [0]</b>           |
| Hemorrhage <sup>6</sup> (all)   | 1            | 0.5%                 | 3                        | 0.7%        | 99.4% [0.5]                              | 97.3% [1.4]                 |
| Hemorrhage (major)              | 1            | 0.5%                 | 1                        | 0.2%        | 100.0% [0]                               | 99.1% [0.9]                 |
| Perivalvular Leak (all)         | 4            | 2.2%                 | 3                        | 0.7%        | 96.7% [1.3]                              | 96.7% [1.3]                 |
| Perivalvular Leak (major)       | 1            | 0.5%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |
| Nonstructural Valve Dysfunction | 0            | 0.0%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |
| Reoperation (valve-related)     | 2            | 1.1%                 | 3                        | 0.7%        | 97.8% [1.1]                              | 97.2% [1.2]                 |
| Structural Valve Dysfunction    | 0            | 0.0%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |
| Thromboembolism                 | 1            | 0.5%                 | 7                        | 1.7%        | 97.8% [1.1]                              | 93.9% [2.5]                 |
| Thrombosis                      | 0            | 0.0%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |

Notes:

1. Data does not include results from double valve replacement.
2. Late events calculated as linearized rates based on total patient-years.
3. Freedom from event was calculated based on the method of Kaplan-Meier. SE = Standard Error.
4. n = number of patients in each category; N = total number of study patients.
5. Blood studies conducted at a core laboratory established that the valve creates a low level of fully compensated hemolysis typified by an increase in SLDH with a mean within normal range, a decrease in haptoglobin to below normal in 69% Aortic Valve Replacement (AVR) and 65% Mitral Valve Replacement (MVR) patients at 1-year, and all other analytes within normal range.
6. The anticoagulant agents used were reported. The target International Normalized Ratio was 2.5 to 3.5 in AVR and 3.0 to 4.5 in MVR.

**Table 4: Mitral Replacement Observed Adverse Event Rates<sup>1</sup>**

All patients implanted, N = 229, Cumulative follow-up = 417.9 patient-years

| Complication                    | Early Events |                      | Late Events <sup>2</sup> |             | Freedom from Event <sup>3</sup> , % [SE] |                             |
|---------------------------------|--------------|----------------------|--------------------------|-------------|--|-----------------------------|
|                                 | n            | % (n/N) <sup>4</sup> | n                        | %/pt-yr     | 1 Year Postoperative (n=134)             | 3 Year Postoperative (n=44) |
| Mortality (all)                 | 9            | 3.9%                 | 9                        | 2.2%        | 95.4% [1.4]                              | 89.2% [2.7]                 |
| Mortality (valve-related)       | 1            | 0.4%                 | 2                        | 0.5%        | 99.5% [0.5]                              | 97.2% [1.7]                 |
| Endocarditis                    | 0            | 0.0%                 | 3                        | 0.7%        | 99.0% [0.7]                              | 99.0% [0.7]                 |
| Explant                         | 1            | 0.4%                 | 3                        | 0.7%        | 98.0% [1.0]                              | 98.0% [1.0]                 |
| <b>Hemolysis<sup>5</sup></b>    | <b>0</b>     | <b>0.0%</b>          | <b>0</b>                 | <b>0.0%</b> | <b>100.0% [0]</b>                        | <b>100.0% [0]</b>           |
| Hemorrhage <sup>6</sup> (all)   | 4            | 1.8%                 | 6                        | 1.4%        | 96.4% [1.3]                              | 94.4% [2.0]                 |
| Hemorrhage (major)              | 4            | 1.8%                 | 2                        | 0.5%        | 97.0% [1.2]                              | 97.0% [1.2]                 |
| Perivalvular Leak (all)         | 2            | 0.9%                 | 3                        | 0.7%        | 98.0% [1.0]                              | 97.1% [1.2]                 |
| Perivalvular Leak (major)       | 1            | 0.4%                 | 1                        | 0.2%        | 99.4% [0.6]                              | 99.4% [0.6]                 |
| Nonstructural Valve Dysfunction | 0            | 0.0%                 | 1                        | 0.2%        | 100.0% [0]                               | 99.1% [0.9]                 |
| Reoperation (valve-related)     | 3            | 1.3%                 | 5                        | 1.2%        | 97.0% [1.2]                              | 97.0% [1.2]                 |
| Structural Valve Dysfunction    | 0            | 0.0%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |
| Thromboembolism                 | 2            | 0.9%                 | 7                        | 1.7%        | 97.0% [1.2]                              | 96.3% [1.4]                 |
| Thrombosis                      | 0            | 0.0%                 | 0                        | 0.0%        | 100.0% [0]                               | 100.0% [0]                  |

Notes:

1. Data does not include results from double valve replacement.
2. Late events calculated as linearized rates based on total patient-years.
3. Freedom from event was calculated based on the method of Kaplan-Meier. SE = Standard Error.
4. n = number of patients in each category; N = total number of study patients.
5. Blood studies conducted at a core laboratory established that the valve creates a low level of fully compensated hemolysis typified by an increase in SLDH with a mean within normal range, a decrease in haptoglobin to below normal in 69% AVR and 65% MVR patients at 1-year, and all other analytes within normal range.
6. The anticoagulant agents used were reported. The target International Normalized Ratio was 2.5 to 3.5 in AVR and 3.0 to 4.5 in MVR.

**Table 5: Preoperative Patient Demographics****Aortic Preoperative Patient Demographics**All patients implanted, N = 184,  
Cumulative follow-up = 411.8 patient-years

| Patient Characteristic         | N                 | % (n/N) <sup>1</sup> |
|--------------------------------|-------------------|----------------------|
| <b>Age at implant in years</b> | <b>60.2 ± 8.4</b> |                      |
| <b>Gender:</b>                 |                   |                      |
| • Male                         | 121               | 65.8%                |
| • Female                       | 63                | 34.2%                |
| <b>NYHA Classification:</b>    |                   |                      |
| • I                            | 9                 | 4.9%                 |
| • II                           | 91                | 49.5%                |
| • III                          | 79                | 42.9%                |
| • IV                           | 5                 | 2.7%                 |
| • Unknown                      | 0                 | 0.0%                 |
| <b>Valve Lesion:</b>           |                   |                      |
| • Stenosis                     | 86                | 46.7%                |
| • Insufficiency                | 39                | 21.2%                |
| • Mixed                        | 59                | 32.1%                |
| • Other                        | 0                 | 0%                   |

Notes: 1. n = number of patients in each category; N = total number of study patients.

**Mitral Preoperative Patient Demographics**All patients implanted, N = 229,  
Cumulative follow-up = 417.9 patient-years

| Patient Characteristic         | N                  | % (n/N) <sup>1</sup> |
|--------------------------------|--------------------|----------------------|
| <b>Age at implant in years</b> | <b>59.2 ± 10.6</b> |                      |
| <b>Gender:</b>                 |                    |                      |
| • Male                         | 86                 | 37.6%                |
| • Female                       | 143                | 62.4%                |
| <b>NYHA Classification:</b>    |                    |                      |
| • I                            | 5                  | 2.2%                 |
| • II                           | 68                 | 29.7%                |
| • III                          | 134                | 58.5%                |
| • IV                           | 18                 | 7.9%                 |
| • Unknown                      | 4                  | 1.7%                 |
| <b>Valve Lesion:</b>           |                    |                      |
| • Stenosis                     | 29                 | 12.7%                |
| • Insufficiency                | 111                | 48.5%                |
| • Mixed                        | 87                 | 38.0%                |
| • Other                        | 2                  | 0.9%                 |

Notes: 1. n = number of patients in each category; N = total number of study patients.



**Table 6: Operative Patient Demographics****Operative Aortic Patient Demographics**

All patients implanted, N = 184,  
Cumulative follow-up = 411.8 patient-years

| Variable                             | Category <sup>1</sup>               | n                     | % (n/N) <sup>2</sup> |       |
|--------------------------------------|-------------------------------------|-----------------------|----------------------|-------|
| Etiology <sup>3</sup>                | Calcific                            | 92                    | 50.0%                |       |
|                                      | Degenerative                        | 51                    | 27.7%                |       |
|                                      | Rheumatic                           | 24                    | 13.0%                |       |
|                                      | Congenital                          | 18                    | 9.8%                 |       |
|                                      | Endocarditis                        | 8                     | 4.4%                 |       |
|                                      | Prosthetic Valve Dysfunction        | 0                     | 0.0%                 |       |
|                                      | Other                               | 6                     | 3.3%                 |       |
|                                      | Concomitant Procedures <sup>3</sup> | None                  | 141                  | 76.7% |
| Coronary Artery Bypass Graft         |                                     | 21                    | 11.4%                |       |
| Myotomy                              |                                     | 10                    | 5.4%                 |       |
| Mitral Repair                        |                                     | 5                     | 2.7%                 |       |
| Aorta Repair or Replacement          |                                     | 4                     | 2.2%                 |       |
| Tricuspid Repair                     |                                     | 1                     | 0.5%                 |       |
| Muscle Bridge                        |                                     | 1                     | 0.5%                 |       |
| Tricuspid Replacement                |                                     | 0                     | 0.0%                 |       |
| Explant of Annuloplasty Ring         |                                     | 0                     | 0.0%                 |       |
| Maze Procedure                       |                                     | 0                     | 0.0%                 |       |
| Closure of Atrial Appendage          |                                     | 0                     | 0.0%                 |       |
| Ventricular Aneurysm Repair          |                                     | 0                     | 0.0%                 |       |
| Other                                |                                     | 0                     | 0.0%                 |       |
| Pre-existing Conditions <sup>3</sup> |                                     | Systemic Hypertension | 90                   | 48.9% |
|                                      |                                     | Hyperlipidemia        | 83                   | 45.1% |
|                                      | Angina                              | 42                    | 22.8%                |       |
|                                      | Coronary Artery Disease             | 42                    | 22.8%                |       |
|                                      | Diabetes Mellitus                   | 33                    | 17.9%                |       |
|                                      | Atrial Arrhythmias                  | 25                    | 13.6%                |       |
|                                      | Left Ventricular Dysfunction        | 23                    | 12.5%                |       |
|                                      | Congestive Heart Failure            | 22                    | 12.0%                |       |
|                                      | Myocardial Infarction               | 12                    | 6.5%                 |       |
|                                      | Cerebrovascular Accident            | 10                    | 5.4%                 |       |
|                                      | Carotid Artery Disease              | 7                     | 3.8%                 |       |
|                                      | Endocarditis                        | 4                     | 2.2%                 |       |
|                                      | Cardiomyopathy                      | 3                     | 1.6%                 |       |
|                                      | Pacemaker Implant                   | 2                     | 1.1%                 |       |
|                                      | Coronary Artery Bypass Graft        | 1                     | 0.5%                 |       |
|                                      | Previous Aortic Valve Replacement   | 1                     | 0.5%                 |       |
|                                      | Previous Mitral Valve Replacement   | 0                     | 0.0%                 |       |
|                                      | Other                               | 27                    | 14.8%                |       |
|                                      | Valve Size                          | 19 mm                 | 17                   | 9.2%  |
|                                      |                                     | 21 mm                 | 35                   | 19.0% |
| 23 mm                                |                                     | 70                    | 38.0%                |       |
| 25 mm                                |                                     | 38                    | 20.6%                |       |
| 27/29 mm                             |                                     | 24                    | 13.0%                |       |

## Notes:

1. Ordered by frequency of occurrence, except for valve size.
2. n = number of patients in each category; N = total number of study patients.
3. May be more than one per patient.

**Operative Mitral Patient Demographics**

All patients implanted, N = 229,  
Cumulative follow-up = 417.9 patient-years

| Variable                             | Category <sup>1</sup>                 | N    | % (n/N) <sup>2</sup> |
|--------------------------------------|---------------------------------------|------|----------------------|
| Etiology <sup>3</sup>                | Rheumatic                             | 86   | 37.6%                |
|                                      | Degenerative                          | 62   | 27.1%                |
|                                      | Calcific                              | 36   | 15.7%                |
|                                      | Endocarditis                          | 16   | 7.0%                 |
|                                      | Prosthetic Valve Dysfunction          | 6    | 2.6%                 |
|                                      | Congenital                            | 4    | 1.8%                 |
|                                      | Other                                 | 38   | 16.6%                |
|                                      | Concomitant Procedures <sup>3</sup>   | None | 130                  |
| Coronary Artery Bypass Graft         |                                       | 44   | 19.2%                |
| Tricuspid Repair                     |                                       | 22   | 9.6%                 |
| Closure of Atrial Appendage          |                                       | 12   | 5.2%                 |
| Mitral Repair                        |                                       | 12   | 5.2%                 |
| Maze Procedure                       |                                       | 12   | 5.2%                 |
| Septal Defect Closure                |                                       | 8    | 3.5%                 |
| Ventricular Aneurysm Repair          |                                       | 3    | 1.3%                 |
| Muscularization                      |                                       | 2    | 0.9%                 |
| Tricuspid Replacement                |                                       | 1    | 0.4%                 |
| Explant of Annuloplasty Ring         |                                       | 1    | 0.4%                 |
| Pre-existing Conditions <sup>3</sup> | Atrial Arrhythmias                    | 137  | 59.3%                |
|                                      | Pulmonary Hypertension                | 108  | 46.8%                |
|                                      | Systemic Hypertension                 | 88   | 38.1%                |
|                                      | Hyperlipidemia                        | 88   | 38.1%                |
|                                      | Congestive Heart Failure              | 80   | 34.6%                |
|                                      | Other                                 | 77   | 33.3%                |
|                                      | Coronary Artery Disease               | 67   | 29.0%                |
|                                      | Cigarette Smoker                      | 64   | 27.7%                |
|                                      | Left Ventricular Dysfunction          | 47   | 20.4%                |
|                                      | Cerebrovascular Accident              | 43   | 18.6%                |
|                                      | Diabetes Mellitus                     | 40   | 17.3%                |
|                                      | Angina                                | 38   | 16.4%                |
|                                      | Myocardial Infarction                 | 30   | 13.0%                |
|                                      | Hyperthyroidism                       | 27   | 11.7%                |
|                                      | Chronic Obstructive Pulmonary Disease | 25   | 10.8%                |
|                                      | Endocarditis                          | 18   | 7.8%                 |
|                                      | Gastrointestinal Ulcer                | 18   | 7.8%                 |
|                                      | Chronic Kidney Failure                | 13   | 5.6%                 |
|                                      | Carotid Artery Disease                | 12   | 5.2%                 |
|                                      | Coronary Artery Bypass Graft          | 10   | 4.4%                 |
| Cancer                               | 10                                    | 4.4% |                      |
| Previous Mitral Valve Replacement    | 9                                     | 3.9% |                      |
| Cardiomyopathy                       | 8                                     | 3.5% |                      |
| Pacemaker Implant                    | 6                                     | 2.6% |                      |
| Valve Size                           | 25 mm                                 | 33   | 14.4%                |
|                                      | 27/29 mm                              | 131  | 57.2%                |
|                                      | 31/33 mm                              | 65   | 28.4%                |

**Table 7: Number Implanted and Years by Valve Size****Number of Aortic Patients Implanted and Number of Patient-years by Valve Size**

All patients implanted, N = 184,  
Cumulative follow-up = 411.8 patient-years

|                                     | Numbers by Valve size |       |       |       |          | Total |
|-------------------------------------|-----------------------|-------|-------|-------|----------|-------|
|                                     | 19 mm                 | 21 mm | 23 mm | 25 mm | 27/29 mm |       |
| <b>Number of Patients Implanted</b> | 17                    | 35    | 70    | 38    | 24       | 184   |
| <b>Number of Patient-years</b>      | 36.9                  | 82.2  | 151.5 | 85.9  | 55.3     | 411.8 |

**Number of Mitral Patients Implanted and Number of Patient-years by Valve Size**

All patients implanted, N = 229,  
Cumulative follow-up = 417.9 patient-years

|                                     | Numbers by Valve size |          |          |  | Total |
|-------------------------------------|-----------------------|----------|----------|--|-------|
|                                     | 25 mm                 | 27/29 mm | 31/33 mm |  |       |
| <b>Number of Patients Implanted</b> | 33                    | 131      | 65       |  | 229   |
| <b>Number of Patient-years</b>      | 60.2                  | 239.1    | 118.6    |  | 417.9 |

**Table 8: Valve Effectiveness Outcomes****Aortic Effectiveness Outcomes, Functional New York Heart (NYHA) Classification<sup>1</sup>**

All patients implanted, N = 184,  
Cumulative follow-up = 411.8 patient-years

| NYHA Class                      | Preoperative Assessment (Nd = 184) |      | Postoperative Assessments                               |          |  |          |  |          |
|---------------------------------|------------------------------------|------|---|----------|--|----------|--|----------|
|                                 |                                    |      | 1 Year (10-14 Months) (Nf = 138, Nd = 129) <sup>2</sup> |          | 2 Year (22-26 Months) (Nf = 66, Nd = 66) |          | 3 Year (34-38 Months) (Nf = 37, Nd = 36) |          |
|                                 |                                    |      | n <sup>3</sup>  | % (n/Nd) | n  | % (n/Nd) | n  | % (n/Nd) |
| <b>I</b>                        | 9                                  | 4.9  | 83  | 64.3     | 48                                       | 72.7     | 20                                       | 55.6     |
| <b>II</b>                       | 91                                 | 49.5 | 35  | 27.1     | 12                                       | 18.2     | 10                                       | 27.8     |
| <b>III</b>                      | 79                                 | 42.9 | 4   | 3.1      | 6  | 9.1      | 4  | 11.1     |
| <b>IV</b>                       | 5                                  | 2.7  | 0   | 0        | 0  | 0        | 0  | 0        |
| <b>Undetermined<sup>4</sup></b> | 0                                  | 0    | 7   | 5.4      | 0  | 0        | 2  | 5.6      |
| <b>Missing<sup>5</sup></b>      | 0                                  | N/A  | 9   | N/A      | 0  | N/A      | 1  | N/A      |

Notes:

1. Data does not include results from double valve replacement.
2. Nf = number of patients followed (reproduced from Figure 2); Nd = number of patients for which NYHA data were collected (not including missing).
3. n = number of patients in each category.
4. Undetermined means data were collected but Class could not be determined during exam
5. Missing refers to the difference between the number of patients followed, Nf, and the number of patients for which NYHA data were collected, Nd.

**Mitral Effectiveness Outcomes, Functional New York Heart (NYHA) Classification<sup>1</sup>**

All patients implanted, N = 229,  
Cumulative follow-up = 417.9 patient-years

| NYHA Class                      | Preoperative Assessment (Nd = 229) |      | Postoperative Assessments                               |          |  |          |  |          |
|---------------------------------|------------------------------------|------|---|----------|--|----------|--|----------|
|                                 |                                    |      | 1 Year (10-14 Months) (Nf = 134, Nd = 127) <sup>2</sup> |          | 2 Year (22-26 Months) (Nf = 74, Nd = 69) |          | 3 Year (34-38 Months) (Nf = 44, Nd = 42) |          |
|                                 |                                    |      | n <sup>3</sup>  | % (n/Nd) | n  | % (n/Nd) | n  | % (n/Nd) |
| <b>I</b>                        | 5                                  | 2.2  | 85  | 66.9     | 35                                       | 50.7     | 14                                       | 33.3     |
| <b>II</b>                       | 68                                 | 29.7 | 29  | 22.8     | 24                                       | 34.8     | 22                                       | 52.4     |
| <b>III</b>                      | 134                                | 58.5 | 5   | 3.9      | 5  | 7.2      | 6  | 14.3     |
| <b>IV</b>                       | 18                                 | 7.9  | 0   | 0        | 1  | 1.4      | 0  | 0        |
| <b>Undetermined<sup>4</sup></b> | 4                                  | 1.7  | 8   | 6.3      | 4  | 5.8      | 0  | 0        |
| <b>Missing<sup>5</sup></b>      | 0                                  | N/A  | 7   | N/A      | 5  | N/A      | 2  | N/A      |

Notes:

1. Data does not include results from double valve replacement.
2. Nf = number of patients followed (reproduced from Figure 2); Nd = number of patients for which NYHA data were collected (not including missing).
3. n = number of patients in each category.
4. Undetermined means data were collected but Class could not be determined during exam
5. Missing refers to the difference between the number of patients followed, Nf, and the number of patients for which NYHA data were collected, Nd.

**Table 9: Effectiveness Outcomes, Hemodynamic Results<sup>1</sup>**

**Effectiveness Outcomes, Aortic Hemodynamic Results<sup>1</sup>**

All patients implanted, N = 184,  
Cumulative follow-up = 411.8 patient-years

| Hemodynamic Parameter  | Results by Valve Size            |                       |                     |                       |                     |                       |                     |                       |                     |                       |
|--|----------------------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|
|  | 19 mm                            |                       | 21 mm               |                       | 23 mm               |                       | 25 mm               |                       | 27/29 mm            |                       |
| <b>Early Postoperation (&lt; 30 days), N<sub>i</sub><sup>2</sup> = 184</b>                         |                                  |                       |                     |                       |                     |                       |                     |                       |                     |                       |
| Mean Gradient <sup>3</sup>   | N <sub>d</sub> <sup>4</sup> = 20 |                       | N <sub>d</sub> = 31 |                       | N <sub>d</sub> = 58 |                       | N <sub>d</sub> = 33 |                       | N <sub>d</sub> = 20 |                       |
| •Mean ± SD   | 11.6 ± 4.5                       |                       | 9.4 ± 3.6           |                       | 8.4 ± 4.3           |                       | 7.5 ± 3.8           |                       | 6.1 ± 2.9           |                       |
| •Min, max  | 5.6, 21.5                        |                       | 4.0, 18.4           |                       | 2.0, 26.4           |                       | 2.1, 18.6           |                       | 1.0, 11.5           |                       |
| EOA <sup>5</sup>   | N <sub>d</sub> = 19              |                       | N <sub>d</sub> = 31 |                       | N <sub>d</sub> = 57 |                       | N <sub>d</sub> = 33 |                       | N <sub>d</sub> = 20 |                       |
| •Mean ± SD   | 1.4 ± 0.2                        |                       | 1.8 ± 0.3           |                       | 2.1 ± 0.5           |                       | 2.5 ± 0.8           |                       | 2.8 ± 0.4           |                       |
| •Min, max  | 1.1, 1.9                         |                       | 1.3, 2.4            |                       | 1.0, 3.6            |                       | 0.9, 4.3            |                       | 1.9, 3.5            |                       |
| Regurgitation <sup>6</sup>   | N <sub>d</sub> = 22              |                       | N <sub>d</sub> = 40 |                       | N <sub>d</sub> = 72 |                       | N <sub>d</sub> = 38 |                       | N <sub>d</sub> = 24 |                       |
|  | n <sup>7</sup>                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | N                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) |
| •0   | 9                                | 40.9%                 | 14                  | 35.0%                 | 31                  | 43.1%                 | 19                  | 50.0%                 | 9                   | 37.5%                 |
| •1-2+  | 12                               | 54.6%                 | 25                  | 62.5%                 | 37                  | 51.4%                 | 19                  | 50.0%                 | 13                  | 54.2%                 |
| •3+  | 0                                | 0.0%                  | 0                   | 0.0%                  | 2                   | 2.8%                  | 0                   | 0.0%                  | 0                   | 0.0%                  |
| •4+  | 0                                | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  |
| •Not available   | 1                                | 4.6%                  | 1                   | 2.5%                  | 2                   | 2.8%                  | 0                   | 0.0%                  | 2                   | 8.3%                  |
| <b>1 Year Postoperation, N<sub>i</sub> = 138</b>   |                                  |                       |                     |                       |                     |                       |                     |                       |                     |                       |
| Mean Gradient  | N <sub>d</sub> = 13              |                       | N <sub>d</sub> = 22 |                       | N <sub>d</sub> = 55 |                       | N <sub>d</sub> = 24 |                       | N <sub>d</sub> = 16 |                       |
| •Mean ± SD   | 9.7 ± 2.6                        |                       | 7.7 ± 2.8           |                       | 6.6 ± 3.0           |                       | 3.7 ± 2.2           |                       | 5.6 ± 2.9           |                       |
| •Min, max  | 5.7, 14.3                        |                       | 3.1, 15.2           |                       | 2.0, 16.0           |                       | 0.5, 11.3           |                       | 1.0, 10.8           |                       |
| EOA  | N <sub>d</sub> = 13              |                       | N <sub>d</sub> = 22 |                       | N <sub>d</sub> = 54 |                       | N <sub>d</sub> = 25 |                       | N <sub>d</sub> = 16 |                       |
| •Mean ± SD   | 1.4 ± 0.3                        |                       | 1.9 ± 0.4           |                       | 2.3 ± 0.6           |                       | 2.8 ± 0.8           |                       | 2.8 ± 0.6           |                       |
| •Min, max  | 0.9, 1.8                         |                       | 1.2, 2.9            |                       | 1.0, 4.1            |                       | 0.8, 4.2            |                       | 2.0, 4.1            |                       |
| Regurgitation  | N <sub>d</sub> = 16              |                       | N <sub>d</sub> = 28 |                       | N <sub>d</sub> = 60 |                       | N <sub>d</sub> = 30 |                       | N <sub>d</sub> = 21 |                       |
|  | n                                | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | N                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) |
| •0   | 4                                | 25.0%                 | 6                   | 21.4%                 | 24                  | 40.0%                 | 12                  | 40.0%                 | 5                   | 23.8%                 |
| •1-2+  | 11                               | 68.8%                 | 21                  | 75.0%                 | 33                  | 55.0%                 | 16                  | 53.3%                 | 15                  | 71.4%                 |
| •3+  | 0                                | 0.0%                  | 0                   | 0.0%                  | 2                   | 3.3%                  | 2                   | 6.7%                  | 1                   | 4.8%                  |
| •4+  | 0                                | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  |
| •Not available   | 1                                | 6.2%                  | 1                   | 3.6%                  | 1                   | 1.7%                  | 0                   | 0.0%                  | 0                   | 0.0%                  |
| <b>&gt; 1 Year Postoperation, N<sub>i</sub> = 103 (total of 2 yr (66) and 3 yr (37) follow-up)</b> |                                  |                       |                     |                       |                     |                       |                     |                       |                     |                       |
| Mean Gradient  | N <sub>d</sub> = 17              |                       | N <sub>d</sub> = 29 |                       | N <sub>d</sub> = 61 |                       | N <sub>d</sub> = 30 |                       | N <sub>d</sub> = 18 |                       |
| •Mean ± SD   | 9.0 ± 3.2                        |                       | 8.1 ± 3.2           |                       | 6.6 ± 3.1           |                       | 4.2 ± 2.5           |                       | 5.5 ± 3.0           |                       |
| •Min, max  | 2.2, 14.3                        |                       | 3.5, 16.6           |                       | 2.0, 14.1           |                       | 0.8, 12.8           |                       | 1.0, 10.8           |                       |
| EOA  | N <sub>d</sub> = 17              |                       | N <sub>d</sub> = 29 |                       | N <sub>d</sub> = 60 |                       | N <sub>d</sub> = 31 |                       | N <sub>d</sub> = 18 |                       |
| •Mean ± SD   | 1.5 ± 0.2                        |                       | 1.8 ± 0.5           |                       | 2.3 ± 0.7           |                       | 2.7 ± 0.8           |                       | 2.9 ± 0.8           |                       |
| •Min, max  | 0.9, 1.9                         |                       | 0.7, 2.9            |                       | 1.4, 4.7            |                       | 0.8, 4.2            |                       | 2.0, 4.3            |                       |
| Regurgitation  | N <sub>d</sub> = 20              |                       | N <sub>d</sub> = 37 |                       | N <sub>d</sub> = 68 |                       | N <sub>d</sub> = 36 |                       | N <sub>d</sub> = 25 |                       |
|  | n                                | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) | N                   | % (n/N <sub>d</sub> ) | n                   | % (n/N <sub>d</sub> ) |
| •0   | 5                                | 25.0%                 | 9                   | 24.3%                 | 27                  | 39.7%                 | 17                  | 47.2%                 | 7                   | 28.0%                 |
| •1-2+  | 12                               | 60.0%                 | 25                  | 67.6%                 | 37                  | 54.4%                 | 16                  | 44.4%                 | 17                  | 68.0%                 |
| •3+  | 2                                | 10.0%                 | 0                   | 0.0%                  | 3                   | 4.4%                  | 2                   | 5.6%                  | 1                   | 4.0%                  |
| •4+  | 0                                | 0.0%                  | 0                   | 0.0%                  | 0                   | 0.0%                  | 1                   | 2.8%                  | 0                   | 0.0%                  |
| •Not available   | 1                                | 5.0%                  | 3                   | 8.1%                  | 1                   | 1.5%                  | 0                   | 0.0%                  | 0                   | 0.0%                  |

Notes:

- Hemodynamic evaluations were performed using transthoracic echocardiography (TTE) and in some cases, transesophageal echocardiography (TEE). Data does include results from double valve replacement.
- N<sub>i</sub> = number of patients followed (reproduced from Figure 2).
- Mean gradient represents the pressure drop measured across the valve in mmHg.
- N<sub>d</sub> = number of patients for which hemodynamic data were collected.
- EOA = effective orifice area measured in cm<sup>2</sup>.
- Regurgitation represents the valvular backflow of blood due to normal leakage and perivalvular leakage; 0 = none, 1+ = mild, 2+ = moderate, 3+ = moderate/severe, 4+ = severe.
- n = number of patients in each category.

**Effectiveness Outcomes, Mitral Hemodynamic Results<sup>1</sup>**

All patients implanted, N = 229,  
Cumulative follow-up = 417.9 patient-years

| Hemodynamic Parameter  | Results by Valve Size |                       |                      |                       |                     |                       |
|--|-----------------------|-----------------------|----------------------|-----------------------|---------------------|-----------------------|
|  | 25 mm                 |                       | 27/29 mm             |                       | 31/33 mm            |                       |
| <b>Early Postoperation (&lt; 30 days), N<sub>i</sub><sup>2</sup> = 216</b> |                       |                       |                      |                       |                     |                       |
| Mean Gradient <sup>3</sup>   | N <sub>d</sub> = 31   |                       | N <sub>d</sub> = 117 |                       | N <sub>d</sub> = 59 |                       |
| •Mean ± SD   | 4.3 ± 1.3             |                       | 4.3 ± 1.6            |                       | 4.5 ± 2.2           |                       |
| •Min, max  | 1.7, 7.5              |                       | 1.2, 10.0            |                       | 1.0, 11.7           |                       |
| EOA <sup>5</sup>   | N <sub>d</sub> = 25   |                       | N <sub>d</sub> = 97  |                       | N <sub>d</sub> = 53 |                       |
| •Mean ± SD   | 2.4 ± 0.8             |                       | 2.2 ± 0.6            |                       | 2.2 ± 0.8           |                       |
| •Min, max  | 0.9, 4.2              |                       | 1.0, 4.3             |                       | 0.8, 4.4            |                       |
| Regurgitation <sup>6</sup>   | N <sub>d</sub> = 28   |                       | N <sub>d</sub> = 104 |                       | N <sub>d</sub> = 56 |                       |
|  | n                     | % (n/N <sub>d</sub> ) | N                    | % (n/N <sub>d</sub> ) | N                   | % (n/N <sub>d</sub> ) |
| •0   | 20                    | 71.4%                 | 73                   | 70.2%                 | 40                  | 71.4%                 |
| •1-2+  | 4                     | 14.3%                 | 25                   | 24.0%                 | 16                  | 28.6%                 |
| •3+  | 0                     | 0.0%                  | 0                    | 0.0%                  | 0                   | 0.0%                  |
| •4+  | 0                     | 0.0%                  | 0                    | 0.0%                  | 0                   | 0.0%                  |
| •Not available   | 4                     | 14.3%                 | 6                    | 5.8%                  | 0                   | 0.0%                  |
| <b>1 Year Postoperation, N<sub>i</sub> = 134</b>                           |                       |                       |                      |                       |                     |                       |
| Mean Gradient  | N <sub>d</sub> = 18   |                       | N <sub>d</sub> = 79  |                       | N <sub>d</sub> = 30 |                       |
| •Mean ± SD   | 3.7 ± 2.0             |                       | 4.4 ± 1.8            |                       | 4.0 ± 1.5           |                       |
| •Min, max  | 1.7, 7.5              |                       | 1.7, 10.0            |                       | 2.0, 7.1            |                       |
| EOA  | N <sub>d</sub> = 15   |                       | N <sub>d</sub> = 70  |                       | N <sub>d</sub> = 28 |                       |
| •Mean ± SD   | 2.1 ± 0.6             |                       | 2.1 ± 0.6            |                       | 2.1 ± 0.6           |                       |
| •Min, max  | 1.2, 3.1              |                       | 0.9, 4.0             |                       | 1.4, 4.3            |                       |
| Regurgitation  | N <sub>d</sub> = 15   |                       | N <sub>d</sub> = 66  |                       | N <sub>d</sub> = 29 |                       |
|  | n                     | % (n/N <sub>d</sub> ) | n                    | % (n/N <sub>d</sub> ) | N                   | % (n/N <sub>d</sub> ) |
| •0   | 11                    | 73.3%                 | 53                   | 80.3%                 | 23                  | 79.3%                 |
| •1-2+  | 3                     | 20.0%                 | 11                   | 16.7%                 | 6                   | 20.7%                 |
| •3+  | 1                     | 6.7%                  | 1                    | 1.5%                  | 0                   | 0.0%                  |
| •4+  | 0                     | 0.0%                  | 0                    | 0.0%                  | 0                   | 0.0%                  |
| •Not available   | 0                     | 0.0%                  | 1                    | 1.5%                  | 0                   | 0.0%                  |



**On-X Life Technologies, Inc.**

1300 East Anderson Lane, Bldg. B Austin, Texas 78752 U.S.A.

TEL: (512) 339-8000 FAX: (512) 339-3636

WEB: [www.onxlti.com](http://www.onxlti.com) EMAIL: [onx@onxlti.com](mailto:onx@onxlti.com)



**CryoLife Europa, Ltd.**

Bramley House, The Guildway, Old Portsmouth Road

Guildford, Surrey, GU3 1LR, United Kingdom



**Moist Heat (Steam)**